By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.

Key Statistics

Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA

Start Up

Company News
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
5 Biotech Stocks at Bargain Basement Prices 6/21/2016 7:42:08 AM
Portola (PTLA) Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting 5/27/2016 9:37:43 AM
Portola (PTLA) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/6/2016 8:06:37 AM
Top 5 Biotech Winners and Losers of Q1 2016 3/31/2016 7:08:32 AM
Portola (PTLA) Craters as Long-Acting Blood Thinner Betrixaban Missed Primary Goal in Phase III Study 3/24/2016 5:50:50 AM
Three Biotechs Face Near-Term FDA Decisions 3/21/2016 6:36:23 AM
Portola (PTLA) Announces Biologics License Application For Andexanet Alfa Accepted For Review By FDA 2/18/2016 7:58:53 AM
Three Underperforming Biopharma Companies Worth Looking At 2/15/2016 6:24:02 AM
Bay Area's Portola (PTLA) Wrangles Andexanet Alfa Deal Worth $120 Million from Bristol-Myers Squibb (BMY), Pfizer (PFE) 2/1/2016 5:42:47 AM